Scrip is part of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction

Euthymics Bioscience, Inc.

Latest From Euthymics Bioscience, Inc.

ADC Competition Heats Up In China But Caution, Pressure Also Mount

After the anti-PD-1/L1 antibody and cell therapy rush, antibody-drug conjugates are quickly gaining attention in China as new technologies and deal-making activity heats up, but one first mover warns of potential over-crowding.

China Deals

Investors Back iOmx’s Focus On Tumor Immune Evasion

The German biopharmaceutical company has been around since 2016, but now has the funding to bring its first candidate into clinical trials by late 2022

Companies Commercial

First Pre-Revenue Biotech IPO Rejection By 'China’s Nasdaq'

The STAR Market of the Shanghai Stock Exchange has called a halt to the potentially third-largest biotech IPO this year in an apparent deterrent to the in-licensing model.

China Financing

Finance Watch: Venture Capital, Debt Financings Led Fundraising Surge In Q2

New VC deals include a $60m series C-1 round for DiCE Molecules a day before it filed paperwork to support a $100m IPO and a $100m financing for China’s IONOVA Life Science. Also, RenovoRx was the 84th company to go public in the US this year and ADC Therapeutics executed a $325m royalty deal. 

Financing Business Strategies
See All

Company Information

  • Industry
  • Biotechnology
  • Pharmaceuticals
  • Other Names / Subsidiaries
    • DOV Pharmaceutical, Inc.
UsernamePublicRestriction

Register